Stakeholder Opinions: Head and Neck Cancer

Publication Date	November 2007
Publisher	Datamonitor
Product Type	Report
Pages	96
ISBN Number	not applicable
Product Code	DAT08822

Price

£2,005.00
approximately: $3,076 | €2,359

PDF

PRINT £2,050 ($3,145 | €2,411)

Order above formats by FAX

Summary

Incidence of head and neck cancer across the seven major markets in 2007 is estimated to total 137,299. Forty percent of these cases present with stage III/IV disease, when patient prognosis is poor. Cisplatin-based therapy continues to dominate treatment, although the toxicities associated with this approach highlights the need for more tolerable alternatives, such as Erbitux.

Scope

Head and neck cancer epidemiology, disease diagnosis and multi-modality treatment approaches
Remaining unmet needs in the treatment of head and neck cancer
Research and analysis of the head and neck cancer pipeline with in-depth clinical and commercial assessment of Phase III candidates
Stakeholder opinions based on qualitative interviews with key opinion leaders from the US and EU

Highlights

The current treatment of concomitant cisplatin-based chemotherapy and radiotherapy cannot be used in all patients due to their associated toxicities. In light of this, opportunity exists for alternative more tolerable therapies to enter the head and neck cancer market.

The majority of head and neck cancer patients present with late stage disease when the survival rate is low. There is therefore a great need for more effective drugs in the metastatic disease setting, in which 5 year survival can be as low as 4%.

Molecular targeted therapies dominate the pipeline. Fully human monoclonal antibodies that also target EGFR are showing encouraging clinical potential while also promising to reduce the infusion-related reactions sometimes seen with Erbitux.

Reasons to Purchase

Gain an insight into the epidemiology trends and major risk factors for head and neck cancer
Identify the limitations of current head and neck cancer treatment options and consider the remaining unmet needs
Acquire a detailed appreciation and impartial perspective of the head and neck cancer pipeline and identify the key products in late-phase development

Content

About Datamonitor Healthcare
About The Oncology Pharmaceutical Analysis Team
Chapter 1 Executive Summary
- Scope Of The Analysis
- Datamonitor Insight Into The Head And Neck Cancer Market
- Related Reports
- Upcoming Reports
Chapter 2 Head And Neck Cancer Overview
- Introduction
- Anatomy Of The Head And Neck
- Symptoms Of Head And Neck Cancer
- Subtypes
- Paranasal Sinuses And Nasal Cavity Cancers
- Oral Cavity Cancers
- Salivary Gland Cancer
- Pharyngeal Cancers
- Laryngeal Cancers
- Staging Head And Neck Cancer
- Tumor, Nodes And Metastasis Classification For Head And Neck Cancer
- Risk Factors In Head And Neck Cancer
- Tobacco And Alcohol Independently Increase Risk
- Human Papilloma Virus Exposure
- Diet May Be Important In Nasopharyngeal Cancer
- Epidemiology
- Crude Incidence Rates For Head And Neck Cancers
- Incidence Of Head And Neck Cancer By Gender In 2007
- Head And Neck Cancer Is More Prevalent In Males
- Forecast Incidence For Head And Neck Cancer By Subtype To 2016
- Incidence Of Head And Neck Cancer Subtypes By Country In 2007
- Oral Cancers Account For 44% Of All Head And Neck Cancers Across The 7mm
- Human Papilloma Virus May Increase Head And Neck Cancer Incidence
Chapter 3 Current Treatment Options For Head And Neck Cancer
- Head And Neck Cancer Treatment Overview
- Radiotherapy Is The Cornerstone Of Head And Neck Cancer Treatment
- Intensity Modulated Radiation Therapy
- Chemoradiotherapy (Crt): Cisplatin Sets The Standard
- Single-Agent Based Chemoradiotherapy (Crt)
- Multi-Agent Based Chemoradiotherapy (Crt)
- Cisplatin, 5-Flurouracil And Radiotherapy
- Cisplatin, Paclitaxel And Radiotherapy
- 5-Fluorouracil, Hydroxyurea And Radiotherapy (Fhx)
- Paclitaxel, 5-Fluorouracil, Hydroxyurea And Radiotherapy (Tfhx)
- Can Induction Chemotherapy Control Distant Metastasis?
- Taxotere Sets A New Induction Standard
- Paclitaxel-Based Induction Therapy
- Erbitux Advances Scchn Treatment
- Clinical Trial Results For Erbitux In Scchn
- Phase Iii Erbitux Trial Meets Primary Endpoint
- Bristol-Myers Squibb/Imclone/Merck Serono Anticipate Further Erbitux Efficacy Data
- Hpv Status May Influence Choice Of Scchn Treatment
Chapter 4 Unmet Needs & Treatment Controversies In Head And Neck Cancer
- Intolerable Toxicities Associated With Current Treatment Options
- Poor Outcome Still Remains For Patients With Metastatic Disease
- Current Scchn Treatment Requires Standardization
- Identifying Responder Groups For Targeted Therapy In Scchn
- Conclusions
Chapter 5 Head And Neck Cancer Product Pipeline
- Head And Neck Cancer Pipeline Overview
- Pipeline Overview
- Late-Phase Product Pipeline For Head And Neck Cancer
- Phase Ii Product Pipeline For Head And Neck Cancer
- Phase I Product Pipeline For Head And Neck Cancer
- Late-Phase Cytotoxic Drug Profile
- Lipoplatin (Regulon)
- Drug Overview
- Key Historical Events
- Clinical Trial Data
- Datamonitor Comments
- Late-Phase Molecular Targeted Therapy Drug Profiles
- Proxinium (Vb4-845; Viventia Biotech)
- Drug Overview
- Key Historical Events
- Clinical Trial Data
- Datamonitor Comments
- Tykerb (Lapatinib; Glaxosmithkline)
- Drug Overview
- Key Historical Events
- Clinical Trial Data
- Datamonitor Comments
- Vectibix (Panitumumab; Amgen),
- Drug Overview
- Key Historical Events
- Clinical Trial Data
- Datamonitor Comments
- Zalutumumab (Humax-Egfr; Genmab)
- Drug Overview
- Key Historical Events
- Clinical Trial Data
- Datamonitor Comments
- Late-Phase Gene Therapy Drug Profile
- Advexin (Ingn-201; Introgen Therapeutics)
- Drug Overview
- Key Historical Events
- Clinical Trial Data
- Datamonitor Comments
Appendix
- Bibliography
- Journals
- Websites
- Other
- Key Opinion Leaders
- Abbreviations
List Of Tables
List Of Figures
- About Datamonitor
- About Datamonitor Healthcare
- About The Oncology Analysis Team
- Disclaimer
List Of Tables
- Table 1: Ajcc Nodes And Metastasis Classification For Head And Neck Cancer
- Table 2: Ajcc Primary Tumor Classification Of Head And Neck Cancers
- Table 3: Crude Incidence Rates (Per 100,000) Of Head And Neck Cancers, 2002
- Table 4: Forecast Incidence Of Head And Neck Cancers, 2002-2016
- Table 5: Overview Of Chemotherapy Regimens Commonly Used In Combination With Radiotherapy In Head And Neck Cancer
- Table 6: A Randomized Study Of Adjuvant Treatment With Cisplatin-Based Chemoradiotherapy Versus Radiotherapy Alone In 167 Patients
- Table 7: Overview Of Cisplatin-5-Fu-Based Chemoradiotherapy Regimens For Scchn
- Table 8: A Phase Iii Rtog Trial Of Erbitux With Cisplatin-Based Crt For The First-Line Treatment Of Patients With Locally Advanced Scchn
- Table 9: Treatment-Related Toxicities In Scchn
- Table 10: Pipeline Drugs In Phase Iii Development For Head And Neck Cancer, 2007
- Table 11: Pipeline Drugs In Phase Ii Development For Head And Neck Cancer, 2007
- Table 12: Pipeline Drugs In Phase I Development For Head And Neck Cancer, 2007
- Table 13: Lipoplatin: Key Historical Events
- Table 14: Ongoing Clinical Trials For Lipoplatin In Advanced Head And Neck Cancer, 2007
- Table 15: Proxinium: Key Historical Events
- Table 16: Ongoing Clinical Trials Involving Proxinium In Head And Neck Cancer, 2007
- Table 17: Tykerb: Key Historical Events
- Table 18: Tykerb Clinical Trials In Head And Neck Cancer, 2007
- Table 19: Vectibix: Key Historical Events
- Table 20: Vectibix Clinical Trials In Head And Neck Cancer, 2007
- Table 21: Zalutumumab: Key Historical Events
- Table 22: Ongoing Clinical Trials For Zalutumumab In Head And Neck Cancer, 2007
- Table 23: Phase I/Ii Study Results Of Zalutumumab In Recurrent Scchn
- Table 24: Advexin: Key Historical Events
- Table 25: Ongoing Clinical Trials For Advexin In Head And Neck Cancer, 2007
- Table 26: Abbreviations Used In Stakeholder Opinions: Head And Neck Cancer, 2007
List Of Figures
- Figure 1: Anatomy Of The Head And Neck
- Figure 2: Positioning Of The Paranasal Sinuses
- Figure 3: The Three Major Salivary Glands
- Figure 4: Subdivisions Of The Pharynx
- Figure 5: Incidence Of Head And Neck Cancers By Gender, 2007
- Figure 6: Incidence Trends Of Head And Neck Cancer Subtypes, 2002-2016
- Figure 7: Incidence Of Head And Neck Cancer Subtypes In The Seven Major Pharmaceutical Markets, 2007
- Figure 8: Treatment Algorithm For Scchn
- Figure 9: A Randomized Phase Iii Trial Of Taxotere-Based Induction Chemotherapy In Patients With Stage Iii/Iv Scchn
- Figure 10: Preliminary Phase Iii Trial Results For Paclitaxel Induction Therapy And Crt In 384 Locally Advanced Scchn Patients
- Figure 11: Phase Iii Trial Results For Erbitux And Radiotherapy In The First-Line Treatment In Patients With Stage Iii/Iv Scchn
- Figure 12: Phase Iii Trial Results For Erbitux And Chemotherapy In The First-Line Treatment Of Recurrent/Metastatic Scchn Patients
- Figure 13: Phase Ii Trial Results For Erbitux And Cisplatin-Based Chemoradiotherapy In The First-Line Treatment Of Locoregionally Advanced Scchn
- Figure 14: 5-Year Survival Rates (%) For Scchn Patients According To Disease Stage
- Figure 15: Preliminary Phase Iii Results For Lipoplatin In Advanced Head And Neck Cancer
- Figure 16: Phase I Results For Proxinium In Advanced Scchn
- Figure 17: Phase Ii Results Of Tykerb In Recurrent/Metastatic Scchn
- Figure 18: Preliminary Phase I Results For Vectibix In Late-Stage Head And Neck Cancer
- Figure 19: Phase Ii Trial Results For Advexin In Recurrent Scchn